Drug intelligence / Profile preview

VES002

Development stage: Preclinical
Lead developer: Vesper Biotechnologies
Modality: Small Molecules
Administration: Oral

Overview

VES002 is an orally administered small molecule sortilin inhibitor developed by Vesper Bio. It is designed to elevate central progranulin levels, which are believed to have a disease-modifying effect in the treatment of Parkinson's disease. The drug is currently undergoing preclinical testing for Parkinson's disease.

Targets

SORT1 (Sortilin)

Beyond the preview

Go deeper on VES002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VES002.

Explore the full profile